0
Sponsors
Ferring Pharmaceuticals A/S, Dermapharm AG, Gcp-Service International West GmbH, Silence Therapeutics PLC, Universitair Medisch Centrum Groningen, Universitair Medisch Centrum Groningen
Conditions
Biliary AtresiaCOVID-19CancerCholangiocarcinomaChronic PainCrohn's diseaseGastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adultsHerpes Zoster
Phase 1
Phase 2
Intravenous Fish Oil based Lipid Emulsion to enhance recovery in High-Risk Cardiac Surgery Patients: a phase II multicenter trial
RecruitingCTIS2023-503490-38-00
Start: 2023-11-15Target: 378Updated: 2025-12-11
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)
CompletedCTIS2023-506837-31-00
Start: 2023-01-27End: 2025-10-20Target: 113Updated: 2025-03-24
A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects with Biliary Atresia, Post-hepatoportoenterostomy
CompletedCTIS2023-503926-37-00
End: 2025-09-17Target: 50Updated: 2025-10-03
(ASK-PD5-CS201) A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson’s Disease
RecruitingCTIS2023-506519-16-00
Start: 2025-04-11Target: 55Updated: 2026-01-27
"Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in patients with dominant liver metastases" "LUTARTERIAL"
RecruitingCTIS2024-514785-39-00
Start: 2021-09-24Target: 23Updated: 2024-11-04
Beta-blockade with landiolol in out-of-hospital cardiac arrest: a randomized, double-blind, placebo-controlled, pilot trial
RecruitingCTIS2024-518949-14-00
Start: 2020-11-30Target: 48Updated: 2024-12-10
"Diagnostic value of 68Ga-FAPI-46 PET/CT in the initial work-up of pancreatic and biliary cancers eligible to a curative treatment" "FAPDIG"
Not yet recruitingCTIS2024-517270-23-00
Target: 120Updated: 2025-07-30
Phase 3
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme
Not yet recruitingCTIS2022-500308-23-00
Target: 115Updated: 2022-11-09
Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
CompletedCTIS2023-503894-39-00
Start: 2023-08-22End: 2024-02-27Target: 110Updated: 2023-10-10
Brain Injury and Ketamine: a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in acute brain injury patients.
RecruitingCTIS2023-505319-19-00
Start: 2021-09-01Target: 100Updated: 2024-02-21
Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin
RecruitingCTIS2022-501415-14-00
Start: 2022-03-08Target: 552Updated: 2025-08-14
Screening for occult malignancy using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism
Active, not recruitingCTIS2024-514703-34-00
Start: 2020-09-08Target: 638Updated: 2024-06-18
A Double-blind, Placebo-Controlled, Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
CompletedCTIS2024-514698-23-00
Start: 2017-05-15End: 2025-10-09Target: 81Updated: 2025-06-19
(WHAT!) – RCT: Open-label randomized controlled trial for the effects of continuous daily use of ethinylestradiol/levonorgestrel (30/150 µg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related migraine and perimenopausal migraine
Not yet recruitingCTIS2024-517127-40-00
Target: 360Updated: 2024-11-29
Evaluation of the efficacy of topical treatment with budesonide in children with Crohn's disease located in the esophagus and/or stomach and/or duodenum - BETHESDa
RecruitingCTIS2024-519269-23-00
Start: 2024-03-27Target: 138Updated: 2025-07-10